Avenue Therapeutics, Inc.
ATXI
$0.58
-$0.01-1.70%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.90% | 6.78% | 11.01% | -25.97% | -11.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.55% | -19.78% | -22.40% | -27.72% | -28.20% |
| Operating Income | 40.66% | 19.78% | 22.40% | 27.72% | 28.20% |
| Income Before Tax | -4.31% | -27.23% | -11.52% | 10.03% | 49.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.31% | -27.23% | -11.52% | 10.03% | 49.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -29.63% | -24.07% | -60.36% | -62.59% | -57.14% |
| Net Income | -4.62% | -27.61% | -12.29% | 9.33% | 49.56% |
| EBIT | 40.66% | 19.78% | 22.40% | 27.72% | 28.20% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 109.49% | 89.06% | 85.04% | 82.93% | 91.07% |
| Normalized Basic EPS | -14.29% | 85.29% | 90.30% | 92.22% | 98.26% |
| EPS Diluted | 109.49% | 89.06% | 85.04% | 82.94% | 91.08% |
| Normalized Diluted EPS | -14.29% | 85.29% | 90.30% | 92.22% | 98.26% |
| Average Basic Shares Outstanding | 366.90% | 620.65% | 816.63% | 932.43% | 707.34% |
| Average Diluted Shares Outstanding | 366.90% | 620.65% | 816.63% | 932.43% | 707.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |